3,072 trials (keyword fallback)
Pheochromocytoma · Paraganglioma
Primary: Number of Participants With Clinical Response (Partial Response + Complete Response) — 5; 0; 5; 2 Participants
Paraganglioma · Pheochromocytoma
Primary: Clinical Benefit Rate (CBR) Which is Defined as Either a Partial Response (PR) Complete Response (CR) or Stable Disease (SD) for ≥ 12 Weeks Measured Using Response…
Malignant Adrenal Gland Pheochromocytoma · Malignant Paraganglioma · Metastatic Adrenal Gland Pheochromocytoma
Primary: Confirmed Tumor Response Rate — 1.0 participants
Pheochromocytoma · Paraganglioma
Primary: MTD of Ultratrace Iobenguane I 131 — 8 mCi/kg
Breast Cancer
Primary: Cohort 1 and Cohort 4: Percentage of Participants With Objective Response (OR) as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors…
Oral Squamous Cell Carcinoma · Neoadjuvant Chemotherapy
Primary: Clinical Response as Measured by RECIST 1.1. Criteria — 5; 5; 8; 7 Participants
Recurrent Neuroendocrine Tumor · Metastatic Neuroendocrine Tumor
Primary: Tumor Response According to RECIST Criteria — 0; 0; 0; 5 Participants
Basal Cell Carcinoma
Primary: Progression Free Survival (PFS) of All Participants — 6; 36 weeks
Carcinoma, Transitional Cell
Primary: Objective Response Rate (ORR) - Central Assessment — 19.5; 21.6; 19.4; 23.8 percentage of participants — p==0.6991
Cancer, Solid Tumor
Primary: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0…
Adult Malignant Fibrous Histiocytoma of Bone · Desmoid Tumor · Endometrial Cancer
Primary: Overall Objective Response — 1; 21; 26 participants
Insular Thyroid Cancer · Recurrent Thyroid Cancer · Stage II Follicular Thyroid Cancer
Primary: Objective Response Rate (PR + CR) Using RECIST/WHO Response Criteria — 0; 0; 0; 0 percentage of participants
Adult Synovial Sarcoma · Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma
Primary: Response Rate (CR + PR) Assessed by RECIST 1.1 (Phase II) — 4; 1; 5; 0 participants
Head and Neck Squamous Cell Carcinoma
Primary: Major Pathologic Response — 22 Participants
Vestibular Schwannoma
Primary: Surgeon Predicted Use of Fluorescein Sodium in Future Cases — 0; 0; 4; 3 participants